ASX:MSBBiotechs
Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives
Mesoblast (ASX:MSB) opened H1 2026 with revenue of US$14.0 million and a basic EPS loss of US$0.04, while trailing 12 month figures in the dataset show revenue of US$65.4 million and a net loss of US$94.4 million. The company has seen revenue move from US$2.5 million in H2 2024 to US$3.2 million in H1 2025 and then to US$14.0 million in H2 2025, with basic EPS losses in those periods ranging between US$0.04 and US$0.05. The latest results therefore keep the focus on how quickly revenue can...